Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding research hub

A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)

This study is looking at a new medicine, VMX-C001, for people who take blood thinners called FXa DOACs and need urgent surgery or a procedure with a high risk of bleeding. It compares VMX-C001 with the usual care, to see if it helps control bleeding better during these important procedures.